Pasithea Therapeutics Corp. KTTA PHARMA
Company Overview
Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumor; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis. The company's lead development candidate is PAS-003, to treat amyotrophic lateral sclerosis. It also intends to develop PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.
Why Investors Should Care
Revenue has grown at a 3130.4% CAGR over the past five years.
Recent Developments
- Trailing 12 Months Year-on-year growth — revenue +3130.4%.
- 5-Year Trend Long-term compounding — revenue CAGR 3130.4%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 3,130.37% |
| 1 Year: | 3,130.37% |
Stock Price Performance
| 1 Year: | -16.57% |
| 6 Months: | -25.13% |
| 3 Months: | +3.99% |
| 1 Month: | +18.15% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)65.70 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 3130.4% over 5 years.
CONS
- Trading 59.2% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | KTTA Pasithea Therapeutics Corp. PHARMA | 0.60 | -0.44 | $20.05M | 0.00% | -37.74% | -65.49% | 3,130.37% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | 13.66K | 13.58K | 218.61K | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | 721 | -1.52K | 132.14K | - | - | - | - | - | - | - | - | - | - |
| Operating Income | -13.97K | -549.61K | -727.95K | -1.27M | -2.08M | -2.61M | -3.86M | -3.21M | -3.83M | -3.79M | -4.04M | -3.95M | -3.00M | -3.68M | -3.81M | -3.11M | -4.88M |
| Net Income | -13.97K | -549.61K | -727.95K | -1.53M | -1.57M | -2.66M | -4.59M | -3.54M | -3.76M | -3.61M | -3.86M | -3.87M | -3.00M | -3.56M | -3.72M | -3.04M | -2.87M |
| Diluted EPS | - | - | -0.09 | -0.17 | -0.01 | -0.02 | -0.01 | -0.01 | -0.01 | 0.00 | -3.70 | -3.71 | -2.87 | -1.61 | -0.66 | -0.41 | -0.12 |
| R&D Expense | - | - | - | - | - | - | 1.28M | 1.10M | 2.03M | 1.62M | 1.75M | 2.36M | 1.58M | 1.73M | 2.15M | 1.36M | 2.94M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 15.06K | 486.56K | - | - | - |
| Gross Profit | -2.21K | - | - | - | - |
| Operating Income | -4.51M | -12.59M | -15.98M | -14.25M | -20.86M |
| Net Income | -2.17M | -13.94M | -15.96M | -13.90M | -20.43M |
| Diluted EPS | -0.21 | -1.76 | -0.42 | -12.69 | -2.91 |
| R&D Expense | - | 2.67M | 8.10M | 7.20M | 7.98M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Total Assets | 247.96K | 53.32M | 45.18M | 26.12M | 16.06M | 60.24M |
| Total Equity | 241.35K | 51.42M | 42.50M | 23.40M | 14.78M | 55.22M |
| Cash & Equivalents | 243.65K | 52.97M | 33.09M | 16.33M | 6.92M | 55.16M |
| Total Liabilities | 6.60K | 1.90M | 2.68M | 2.72M | 1.28M | 5.02M |
| Current Liabilities | 6.60K | 447.28K | 1.88M | 2.63M | 1.12M | 4.97M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -3.17M | -14.56M | - | -13.92M | -15.21M |
| Investing Cash Flow | -21.50K | -2.06M | - | - | 11.00K |
| Financing Cash Flow | 55.93M | -3.21M | - | 4.52M | 63.52M |
| Capital Expenditure | -21.50K | -107.10K | -34.30K | - | - |
| Free Cash Flow | -3.20M | -14.67M | - | - | - |
| Share Buybacks | - | - | 3.73M | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | -14.7% | - | - | - | - |
| Operating Margin % | -29,925.7% | -2,587.3% | - | - | - |
| Net Margin % | -14,430.5% | -2,864.3% | - | - | - |
| ROE % | -4.2% | -32.8% | -68.2% | -94.1% | -37.0% |
| ROCE % | -8.5% | -29.1% | -68.0% | -95.4% | -37.7% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Cable Car Capital, LP | 8.98% | 3.00M | $1.57M |
| 2 | Stonepine Capital Management, LLC | 6.59% | 2.20M | $1.15M |
| 3 | Adage Capital Partners GP L.L.C. | 6.28% | 2.10M | $1.10M |
| 4 | Jupiter Topco LLC | 6.28% | 2.10M | $1.10M |
| 5 | Opaleye Management Inc. | 6.14% | 2.05M | $1.07M |
| 6 | Ameriprise Financial, Inc. | 5.58% | 1.86M | $976.43K |
| 7 | Squadron Capital Management LLC | 2.99% | 1.00M | $523.70K |
| 8 | AdvisorShares Investments, LLC | 2.81% | 937.55K | $490.99K |
| 9 | Vivo Capital, LLC | 1.39% | 465.47K | $243.77K |
| 10 | Persistent Asset Partners Ltd | 0.87% | 290.56K | $152.16K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for KTTA
Pasithea Therapeutics (KTTA) Could Find a Support Soon, Here's Why You Should Buy the Stock Now - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxOTmtuWV9objRLX1BxV09zNzN4M0xNQ0Z6aGRKczVUc29LelItRkhoQjdJeldlVWZ4NHJNQXZDN25iNG5LN3BBLWZqTU5XbjNfbVVRc0pvWTc2RVE4UXRDMktQVDRGZnF6TWgybXZLSzdWeEdrTC1yczl2MEJzQlQ1VUdqMXhCUnEzbHd2aG…
Pasithea management to meet investors at B. Riley health summit in Boston - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxOckZwV3pGemhTSFJteTVjeGxfeW5MVTNSQXNrdnVuVHNWa0k0LUVJTFpLdFpXZDZBY1pUTEc2eFN3MExLZDV1emY5cFRJbTllR1ZJVHdYZGFtZk10RHU0UWp4TFdybzhpUFF3U0sxTU5DZndYZ0RtWDJFV1k3MmlfaWRYY2RVNmE2UkptTU…
Positive Signs As Multiple Insiders Buy Pasithea Therapeutics Stock - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi6wFBVV95cUxNUnBkWkkzeVBxZHBrbVJXMUZmSk5kMUU4alRtd1dHem95OG5Belk2bUVNa0FlRDFHcEN6TlkwSl92THo2bi1Xem1iLVlxRXREajJUakswdTcxSFhNUTEyZ1FPckU5RXNxdzFBWmpvemplZWJuanhqa0gzalA4ajJjcDE0Q2NEakN2a09aUm…
Insider Purchase: 10% owner at $KTTA Buys 100,000 Shares - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxQd0gyN3pxZ28wQ0NyblFNcXhuZGdSdzFHNFI5ZUtYb3RROGtLclN5ZTc5bVhXNm1IV2p0U3JlOENyMWhBYWZJSkF4eDRQUjdfZkFTcVBXR2wwcVA2cWpBSnJkLXpXM3R3VnBIVWxFXzJVWjlXRl9wU194c3hlaEd5X0UtRkxaNk5yMlZfTF…
KTTA - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE1tNUFrNmptOHUwNC1ialkzOWNLN0FFbkRrQlpJSVF1QnhaRkhCZHlfU1NDWWFuRG9pN2xSdEFtMFdVQ1B6VFE?oc=5" target="_blank">KTTA</a> <font color="#6f6f6f">Finviz</font>…
KTTA Forecast — Price Target — Prediction for 2027 - tradingview.com
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE1jNGtvMFNsb3M5c3dBeFhMUFppNklFSXRzVDZ2MjM1TG1PWVB3YWpyZDRYU0RVSXlOaTBuUFRPRUZfb2RTYnczaVRJenp0dWdjd3kxaFZ6c0g1TVByYlI1SDlzWFhzcDhVMmw3dFVLUFIxdGRZajQyUmFR?oc=5" target="_blank">KTT…
KTTA — Frequently Asked Questions
What is the current share price of Pasithea Therapeutics Corp. (KTTA)?
As of 2026-09-19 21:16 PDT, Pasithea Therapeutics Corp. (KTTA) trades at $0.60 on NasdaqCM. Its 52-week range is $0.29 to $1.47.
What is the market capitalisation of KTTA?
Pasithea Therapeutics Corp. (KTTA) has a market capitalisation of $20.05M on NasdaqCM.
What is the P/E ratio of KTTA?
KTTA trades at a trailing price-to-earnings (P/E) ratio of -0.44. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.35.
What is the return on equity (ROE) of KTTA?
KTTA has a return on equity (ROE) of -65.49%. Its return on capital employed (ROCE) is -37.74%.
Is KTTA a good stock to buy?
This page provides a data-driven analysis of Pasithea Therapeutics Corp. (KTTA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.